NCT02898922View on ClinicalTrials.gov

Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 31, 2015

Conditions
Hepatitis B Vaccines
Interventions
BIOLOGICAL

hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae

20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention, China

OTHER_GOV

collaborator

National Institutes for Food and Drug Control, China

OTHER

lead

Shandong Province Centers for Disease Control and Prevention

OTHER

NCT02898922 - Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China | Biotech Hunter | Biotech Hunter